PF-Atlas › Drugs › Dasatinib

Dasatinib

Idiopathic Pulmonary Fibrosis · Senolytics

Clinical trials
3
Mechanism
Senolytics
Development stage
Phase II
Evidence level
Level 2 (Phase II)
Developer
Mayo Clinic

Overview

First senolytic trial in IPF. Intermittent 3-day dosing. Improved 6MWD. Phase III design underway.

Dasatinib clinical trials

NCT04262635 (Phase 2)NCT00764309 (Phase 1)NCT02874989 (Phase 1)

Explore related

Treatment profileSenolyticsAll trialsResearch
Medical disclaimer. This page summarizes research about Dasatinib for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.